Astria Therapeutics, who are developing STAR-0215 for the treatment of hereditary angioedema (HAE), presented information regarding patient preference for efficacy measures when starting on or switching to a new preventative therapy at the 2023 US Hereditary Angioedema Association (HAEA) National Summit in Orlando, Florida from 20-23 July 2023.
Sarah Friedhoff, Director of Patient Advocacy at Astria Therapeutics, presented the following paper at a poster session: People Living with Hereditary Angioedema (HAE) Prioritize Attack-Free Status as a Target for Therapeutic Efficacy.
(Source: Astria Therapeutics)
